A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746
across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia
(CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1
every 21 days at the same dosages and schedule in the study. The secondary objectives are to
characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of
ONO-7746 on CIT.